Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
Cobain E, Pusztai L, Graham C, Whitworth P, Beitsch P, Osborne C, Layeequr Rahman R, Johnson N, Brufsky A, Mahtani R, Gadi V, Hoskins K, Linden H, Mukhtar R, Esserman L, Haan J, Quinn K, Menicucci A, Audeh M, O'Shaughnessy J. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. Journal Of Clinical Oncology 2024, 42: 506-506. DOI: 10.1200/jco.2024.42.16_suppl.506.Peer-Reviewed Original ResearchEarly-stage breast cancerAntigen presenting cellsImmune cell frequenciesImmune activation stateT cellsAntigen presentationB cellsBreast cancerResponse rate to neoadjuvant chemotherapyCell frequencyRate to neoadjuvant chemotherapyResponse rates to immunotherapyRisk of distant recurrenceCD4+ memory T cellsHigh-risk early-stage breast cancerCD8+ T cellsAntigen processingI-SPY 2Major histocompatibilityTumor-infiltrating lymphocytesMemory T cellsIncreased antigen presentationMemory B cellsActivated dendritic cellsImmune therapy response